Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy
Measurement of Oxidative Stress of Retinal Ganglion Cells With and Without Anti-oxidants and Anti-inflammatory Agents in Patients With Glaucoma and Diabetic Retinopathy as Determined by Mitochondrial Flavoprotein Fluorescence
Sponsor: The New York Eye & Ear Infirmary
Terminated
Investigator left the institution
Other terminated trials from The New York Eye & Ear Infirmary
Listed as NCT02984813, this PHASE1 trial focuses on Diabetic Retinopathy and Open-angle Glaucoma and remains terminated or withdrawn. Sponsored by The New York Eye & Ear Infirmary, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE1
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The New York Eye & Ear Infirmary
For direct contact, visit the study record on ClinicalTrials.gov .